



Synthesis and Biological Activity of Antimicrobial Agents, 2nd Volume

Guest Editor:

Dr. Maria Fernanda N. N. Carvalho

Instituto Superior Técnico,
University of Lisbon, 1049-001
Lisbon, Portugal

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editor

Dear Colleague,

You are invited to communicate your recent scientific achievements concerning new strategies to fight microbial infections in the MDPI Special Issue “Synthesis and Biological Activity of Antimicrobial Agents” (2nd Volume). At the moment, infection with the SARS-CoV-2 virus is a threat that has been clearly perceived all over the world. Less widespread and broadcast is the concern regarding microorganisms such as bacteria and fungi, especially for those with depleted immune systems. According to *The Lancet* (Jan 2022), 4.95 million people died in 2019 due to antimicrobial resistance to commercially available antimicrobials.

The aim of this Special Issue is to put together significant research on molecules that have the potential to contribute to reducing the number of fatalities caused by bacteria or fungi as well as controlling emerging microorganisms in agricultural crops and food.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi